Show simple item record

dc.contributor.authorHorne, HN
dc.contributor.authorOh, H
dc.contributor.authorSherman, ME
dc.contributor.authorPalakal, M
dc.contributor.authorHewitt, SM
dc.contributor.authorSchmidt, MK
dc.contributor.authorMilne, RL
dc.contributor.authorHardisson, D
dc.contributor.authorBenitez, J
dc.contributor.authorBlomqvist, C
dc.contributor.authorBolla, MK
dc.contributor.authorBrenner, H
dc.contributor.authorChang-Claude, J
dc.contributor.authorCora, R
dc.contributor.authorCouch, FJ
dc.contributor.authorCuk, K
dc.contributor.authorDevilee, P
dc.contributor.authorEaston, DF
dc.contributor.authorEccles, DM
dc.contributor.authorEilber, U
dc.contributor.authoret al [Incl Mannermaa, A; Tengström, M]
dc.date.accessioned2018-05-04T10:06:25Z
dc.date.available2018-05-04T10:06:25Z
dc.date.issued2018
dc.identifier.urihttps://erepo.uef.fi/handle/123456789/6572
dc.description.abstractE-cadherin (CDH1) is a putative tumor suppressor gene implicated in breast carcinogenesis. Yet, whether risk factors or survival differ by E-cadherin tumor expression is unclear. We evaluated E-cadherin tumor immunohistochemistry expression using tissue microarrays of 5,933 female invasive breast cancers from 12 studies from the Breast Cancer Consortium. H-scores were calculated and case-case odds ratios (OR) and 95% confidence intervals (CIs) were estimated using logistic regression. Survival analyses were performed using Cox regression models. All analyses were stratified by estrogen receptor (ER) status and histologic subtype. E-cadherin low cases (N = 1191, 20%) were more frequently of lobular histology, low grade, >2 cm, and HER2-negative. Loss of E-cadherin expression (score < 100) was associated with menopausal hormone use among ER-positive tumors (ever compared to never users, OR = 1.24, 95% CI = 0.97–1.59), which was stronger when we evaluated complete loss of E-cadherin (i.e. H-score = 0), OR = 1.57, 95% CI = 1.06–2.33. Breast cancer specific mortality was unrelated to E-cadherin expression in multivariable models. E-cadherin low expression is associated with lobular histology, tumor characteristics and menopausal hormone use, with no evidence of an association with breast cancer specific survival. These data support loss of E-cadherin expression as an important marker of tumor subtypes.
dc.language.isoEN
dc.publisherSpringer Nature
dc.relation.ispartofseriesScientific Reports
dc.relation.urihttp://dx.doi.org/10.1038/s41598-018-23733-4
dc.rightsCC BY http://creativecommons.org/licenses/by/4.0/
dc.subjectbreast cancer
dc.subjectrisk factors
dc.titleE-cadherin breast tumor expression, risk factors and survival: Pooled analysis of 5,933 cases from 12 studies in the Breast Cancer Association Consortium
dc.description.versionpublished version
dc.contributor.departmentSchool of Medicine / Clinical Medicine
uef.solecris.id54192384en
dc.type.publicationTieteelliset aikakauslehtiartikkelit
dc.rights.accessrights© Authors
dc.relation.doi10.1038/s41598-018-23733-4
dc.description.reviewstatuspeerReviewed
dc.format.pagerange6574
dc.relation.issn2045-2322
dc.relation.issue1
dc.relation.volume8
dc.rights.accesslevelopenAccess
dc.type.okmA1
uef.solecris.openaccessOpen access -julkaisukanavassa ilmestynyt julkaisu


Files in this item

Thumbnail

This item appears in the following Collection(s)

Show simple item record